Ferric carboxymaltose/iron sucrose/zoledronic acid
- 29 Downloads
An event is serious (based on the ICH definition) when the patient outcome is:
* congenital anomaly
* other medically important event
A 40.5-year-old man developed hypophosphataemia and osteomalacia following treatment with ferric carboxymaltose and iron sucrose for microcytic anaemia. Additionally, zoledronic acid and unspecified glucocorticoid contributed in osteomalacia [not all dosages and routes stated].
The man, with Crohn's disease (CD) presented to osteology outpatient clinic due to diffuse skeletal pain (lumbar and thoracic spine, ribs and lower extremities), progressive loss of mobility and gait disturbance. After clinical worsening (of persisting bone pain and gait disturbance), he received zoledronic acid. However, his symptoms did not improve over the subsequent months, thus, he was hospitalised. He had been receiving calcium and vitamin D supplementation, along with maintenance therapy of...
- Bartko J, et al. Hypophosphatemia, Severe Bone Pain, Gait Disturbance, and Fatigue Fractures After Iron Substitution in Inflammatory Bowel Disease: A Case Report. Journal of Bone and Mineral Research 33: 534-539, No. 3, Mar 2018. Available from: URL: http://doi.org/10.1002/jbmr.3319 - Austria